Could Cosmos Holdings (COSM) Become a Major Disruptor in an Estimated $1.3 Trillion Global Pharma Industry

The health scare has only accelerated the global demand for medication. In fact, according to Fortune Business Insights, in 2020, the health scare “accelerated the demand for effective treatments and drugs worldwide” and caused the global pharmaceutical industry to reach an estimated valuation of $1.3 Trillion. (2)

In addition, they noted there’s an “increasing prevalence of chronic disease and the growing adoption of modern technologies that are leading to the evolving pharmaceuticals sector.” (3) This is why Fortune believes we could see the global pharmaceuticals market size reach nearly $2.15 trillion by 2027 at an estimated CAGR of 7.0%.(3)

One of the top companies benefiting from this pharma rush is Cosmos Holdings (NASDAQ:COSM). Cosmos is a disruptive company that offers customers and shareholders diversified exposure to several in-demand and growing verticals in the pharma and wellness space, including (4): Branded Pharmaceuticals, Generic Pharmaceuticals, Health Products & Food Supplements, Research & Development, Acquisitions, Green leaf derived products, Local & Direct to Pharmacy Wholesale

Clearly, Cosmos and its unique business model may be doing something right. Not only did Cosmos see 2020 revenue growth of about 40% and jaw-dropping gross profit growth of nearly 120%, (9) it reported 15.8% year-over-year growth and a 27.8% sequential increase in revenue for Q2 2021.(1)

But that’s not the company’s biggest news at the moment…In a major company milestone, Cosmos just up listed to the Nasdaq Capital Market (10)


Click HERE to Read 7 Top Reasons To Get Cosmos Holdings On Your Radar Now
Other companies in Cosmos Holdings’s space includes: AmerisourceBergen (NYSE:ABC), McKesson (NYSE:MCK), Henry Schein (NASDAQ:HSIC), Patterson Companies (NASDAQ:PDCO) and PetIQ (NASDAQ:PETQ).

Sources: Source 1:, Source 2:, Source 3:, Source 4:, Source 9:, Source 10:


For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at

Published by Alan Masterson

Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email ( or his Google+ page (